To celebrate Tom Krummel's retirement from Stanford, we gathered for an evening of #storytelling. Tom is continuing as a senior advisor for Biodesign and board chair @FogartyInnov so we're not sure this counts as retirement but we miss you already TK! #healthtech#innovation
Don't miss part 2! @FogartyInnov CEO Andrew Cleeland interviews @joshatnea, an engineer, physician, serial medtech entrepreneur, venture capitalist, musician, artist, wine connoisseur, and the new director of Stanford Biodesign. #medtechtrailblazers https://t.co/eOsbvNLhBv
“One of the greatest thrills in life is to do something that's never been done before. It’s about breaking new ground and improving outcomes for patients.” Watch the 1st #MedTechTrailblazers episode with
@joshatnea, incoming director of @SUBiodesign: https://t.co/3KGO5uIifC
“Hearing that Josh was interested in the director position was like finding out Steph Curry is eligible to play on your college basketball team. We're delighted to welcome him back to Stanford Biodesign.” @PaulYockMD@joshatnea@exploramed@JoshAtCoravin https://t.co/l9b96K7Tsh
.@ExploraMed president Eb Bright: we need strong #patents to turn ideas into products. Yet, because of bad changes to the #patent system, we've seen very little early stage investment going to the small inventors with big ideas. #PatentsMatter
#Healthtech#innovation training: clues that you've uncovered an important problem in healthcare: patient morbidity, poor outcomes, high costs, the comment, "If only I had a way to..." Biodesign Executive Education 2018 #medtech